Lingyu Li

Lingyu Li is a Senior Principal Scientist in Cell Therapy Process Development at Genentech, with extensive experience in the biotechnology field. Previously, Lingyu Li held roles including Associate Director and Senior Scientist at Refuge Biotechnologies, leading significant projects such as the development of the RB340-1 cell therapy product and optimizing CAR-T cell manufacturing processes. Earlier career milestones include research positions at Stanford University, where Lingyu Li focused on CRISPR/Cas9 genome editing and developmental biology, as well as postdoctoral work at The Hospital for Sick Children in Canada. Lingyu Li earned a BS in Biology from Tsinghua University and a Ph.D. in Cell Biology from the University of Chinese Academy of Sciences.